Citadel Advisors
OYST

Citadel Advisors’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Citadel Advisors’s Portfolio OYST Stock Details OYST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-29,511
Closed -$330K – 16227
2022
Q4 		$330K Sell
29,511
-266,547
-90% -$2.58M ﹤0.01% 9103
2022
Q3 		$1.66M Buy
296,058
+72,593
+32% +$455K ﹤0.01% 5944
2022
Q2 		$968K Buy
223,465
+117,584
+111% +$668K ﹤0.01% 7097
2022
Q1 		$1.23M Sell
105,881
-24,805
-19% -$295K ﹤0.01% 7228
2021
Q4 		$2.39M Sell
130,686
-1,813
-1% -$23K ﹤0.01% 5830
2021
Q3 		$1.57M Buy
132,499
+29,396
+29% +$428K ﹤0.01% 6975
2021
Q2 		$1.77M Sell
103,103
-129,103
-56% -$2.45M ﹤0.01% 6888
2021
Q1 		$4.25M Sell
232,206
-50,000
-18% -$1.05M ﹤0.01% 4636
2020
Q4 		$5.31M Buy
282,206
+5,000
+2% +$108K ﹤0.01% 3579
2020
Q3 		$5.85M Sell
277,206
-4,336
-2% -$101K ﹤0.01% 2929
2020
Q2 		$8.13M Buy
281,542
+261,668
+1,317% +$7.89M ﹤0.01% 2464
2020
Q1 		$696K Buy
+19,874
New +$643K ﹤0.01% 5936

Other funds holding OYST

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's OYST Position: Q1 2023 in Review

Citadel Advisors sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q1 2023, closing a stake of 29,511 shares — an estimated $330K sold.

Citadel Advisors first reported a position in OYST in Q1 2020 and held it in 12 quarters. The position peaked at $8.13M in Q2 2020. 1 fund tracked by Wall St. Rank holds OYST as of Q1 2023.

  • Citadel Advisors reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 29,511 Oyster Point Pharma, Inc. Common Stock shares in Q1 2023, an estimated $330K.
  • Citadel Advisors first reported a position in Oyster Point Pharma, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
  • Citadel Advisors's Oyster Point Pharma, Inc. Common Stock position peaked at $8.13M in Q2 2020.
  • 1 fund tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.